Cross-reactivity among and between macrolides, lincosamides, and streptogramins: Study on the French pharmacovigilance database

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Quentin Le Baron, Delphine Bourneau-Martin, Marina Babin, Aurore Gouraud, Marie Tauber, Audrey Fresse, Bénédicte Lebrun-Vignes, Juliette Delaunay, Martine Morisset, Marie Briet
{"title":"Cross-reactivity among and between macrolides, lincosamides, and streptogramins: Study on the French pharmacovigilance database","authors":"Quentin Le Baron,&nbsp;Delphine Bourneau-Martin,&nbsp;Marina Babin,&nbsp;Aurore Gouraud,&nbsp;Marie Tauber,&nbsp;Audrey Fresse,&nbsp;Bénédicte Lebrun-Vignes,&nbsp;Juliette Delaunay,&nbsp;Martine Morisset,&nbsp;Marie Briet","doi":"10.1111/fcp.13005","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Hypersensitivity reactions (HSR) are reported for the macrolides, lincosamides, and streptogramins (MLS) antibiotic family. Data about cross-reactivity among and between MLS remain scarce or controversial.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>The aim of this study was to provide an overview of hypersensitivity cross-reactions among MLSs based on data extracted from the French National Pharmacovigilance Database (FPVD).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Cases of HSR to MLSs reported between January 1985 and December 2019 were extracted from the FPVD using standardized MedDRA queries (SMQ). Cases including an allergological test involving multiple MLSs and giving at least one positive result were included.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of the 8394 cases reviewed, 149 were included. HSR mainly involved pristinamycin (<i>n</i> = 83; 53.2%) and spiramycin (<i>n</i> = 31; 19.9%). HSR to MLS was immediate in 54 cases and delayed in 94 cases. Skin tests represented the majority of the allergological tests performed (<i>n</i> = 728; 84.7%), followed by reintroduction tests (<i>n</i> = 79; 9.2%). Eighty-six cross-reactivities among MLS were identified in 62 cases (41.6%). All the 25 explorations performed for streptogramins showed cross-reactivities, but only 30/253 among macrolides (11.9%). Cross-reactivities between the three MLS were observed in 31/322 (9.6%) of the allergological explorations.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study highlights the possibility of cross-reactivity among and between MLSs. Dermatologists and allergologists managing patients with HSR to MLSs should be aware of a risk of cross-reactivity among the macrolides and between the different classes of MLS and to perform MLSs allergological testing before recommending an alternative antibiotic, especially in severe drug hypersensitivity from the MLS family.</p>\n </section>\n </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/fcp.13005","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fundamental & Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/fcp.13005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Hypersensitivity reactions (HSR) are reported for the macrolides, lincosamides, and streptogramins (MLS) antibiotic family. Data about cross-reactivity among and between MLS remain scarce or controversial.

Objectives

The aim of this study was to provide an overview of hypersensitivity cross-reactions among MLSs based on data extracted from the French National Pharmacovigilance Database (FPVD).

Methods

Cases of HSR to MLSs reported between January 1985 and December 2019 were extracted from the FPVD using standardized MedDRA queries (SMQ). Cases including an allergological test involving multiple MLSs and giving at least one positive result were included.

Results

Of the 8394 cases reviewed, 149 were included. HSR mainly involved pristinamycin (n = 83; 53.2%) and spiramycin (n = 31; 19.9%). HSR to MLS was immediate in 54 cases and delayed in 94 cases. Skin tests represented the majority of the allergological tests performed (n = 728; 84.7%), followed by reintroduction tests (n = 79; 9.2%). Eighty-six cross-reactivities among MLS were identified in 62 cases (41.6%). All the 25 explorations performed for streptogramins showed cross-reactivities, but only 30/253 among macrolides (11.9%). Cross-reactivities between the three MLS were observed in 31/322 (9.6%) of the allergological explorations.

Conclusion

This study highlights the possibility of cross-reactivity among and between MLSs. Dermatologists and allergologists managing patients with HSR to MLSs should be aware of a risk of cross-reactivity among the macrolides and between the different classes of MLS and to perform MLSs allergological testing before recommending an alternative antibiotic, especially in severe drug hypersensitivity from the MLS family.

大环内酯类、林可霉素类和链霉亲和素之间的交叉反应:法国药物警戒数据库研究
背景据报道,大环内酯类、林可霉素类和链霉亲和素类(MLS)抗生素家族存在超敏反应(HSR)。本研究旨在根据从法国国家药物警戒数据库(FPVD)中提取的数据,概述MLS之间的超敏反应。方法使用标准化MedDRA查询(SMQ)从FPVD中提取1985年1月至2019年12月期间报告的MLS超敏反应病例。结果在审查的 8394 个病例中,纳入了 149 个病例。HSR 主要涉及普瑞司霉素(83 例;53.2%)和螺旋霉素(31 例;19.9%)。54例患者立即进行了MLS HSR,94例患者延迟进行了MLS HSR。在进行的过敏原检测中,皮肤试验占大多数(n = 728;84.7%),其次是再引入试验(n = 79;9.2%)。在 62 个病例(41.6%)中发现了 MLS 之间的 86 种交叉反应。对链霉亲和素进行的所有 25 次检测均显示出交叉反应,但在大环内酯类药物中仅有 30/253 例(11.9%)出现交叉反应。在 31/322 例(9.6%)过敏试验中观察到了三种 MLS 之间的交叉反应。皮肤科医生和过敏科医生在管理对 MLS 过敏的 HSR 患者时,应意识到大环内酯类药物之间以及不同类别的 MLS 之间存在交叉反应的风险,并在推荐替代抗生素前进行 MLS 过敏测试,尤其是对 MLS 家族的严重药物过敏者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
6.90%
发文量
111
审稿时长
6-12 weeks
期刊介绍: Fundamental & Clinical Pharmacology publishes reports describing important and novel developments in fundamental as well as clinical research relevant to drug therapy. Original articles, short communications and reviews are published on all aspects of experimental and clinical pharmacology including: Antimicrobial, Antiviral Agents Autonomic Pharmacology Cardiovascular Pharmacology Cellular Pharmacology Clinical Trials Endocrinopharmacology Gene Therapy Inflammation, Immunopharmacology Lipids, Atherosclerosis Liver and G-I Tract Pharmacology Metabolism, Pharmacokinetics Neuropharmacology Neuropsychopharmacology Oncopharmacology Pediatric Pharmacology Development Pharmacoeconomics Pharmacoepidemiology Pharmacogenetics, Pharmacogenomics Pharmacovigilance Pulmonary Pharmacology Receptors, Signal Transduction Renal Pharmacology Thrombosis and Hemostasis Toxicopharmacology Clinical research, including clinical studies and clinical trials, may cover disciplines such as pharmacokinetics, pharmacodynamics, pharmacovigilance, pharmacoepidemiology, pharmacogenomics and pharmacoeconomics. Basic research articles from fields such as physiology and molecular biology which contribute to an understanding of drug therapy are also welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信